Form 13-F position report

VIRPAX PHARMACEUTICALS INC

Reported by MORGAN STANLEY

VRPX CUSIP 928251206 Manager CIK 0000895421

Reported 0 shares, down 499 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q1 2025
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 16 Through Q1 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 16000
2022-03-31 174000
2022-06-30 30000
2022-09-30 0
2022-12-31 669
2023-03-31 118
2023-06-30 162
2023-09-30 120
2023-12-31 48
2024-03-31 0
2024-03-31 64
2024-06-30 8
2024-09-30 10
2024-12-31 190
2025-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

15 quarters
Quarterly reported position history for VIRPAX PHARMACEUTICALS INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2025 Reduced 0 -499 (-100.0%) 0 $0 2025-05-15
Q4 2024 Added 499 +484 (3226.7%) < 0.01% $190 2025-02-14
Q3 2024 Unchanged 15 0 (0.0%) < 0.01% $10 2024-11-14
Q2 2024 Unchanged 15 0 (0.0%) < 0.01% $8 2024-08-14
Q1 2024 New 15 +15 (0.0%) < 0.01% $64 2024-05-15
Q1 2024 Reduced 0 -150 (-100.0%) 0 $0 2024-05-15
Q4 2023 Unchanged 150 0 (0.0%) < 0.01% $48 2024-02-13
Q3 2023 Unchanged 150 0 (0.0%) < 0.01% $120 2023-11-15
Q2 2023 Unchanged 150 0 (0.0%) < 0.01% $162 2023-08-14
Q1 2023 Reduced 150 -926 (-86.1%) < 0.01% $118 2023-05-15
Q4 2022 New 1,076 +1,076 (0.0%) < 0.01% $669 2023-02-14
Q3 2022 Reduced 0 -18,016 (-100.0%) 0 $0 2022-11-14
Q2 2022 Reduced 18,016 -60,495 (-77.1%) < 0.01% $30,000 2022-08-15
Q1 2022 Added 78,511 +73,619 (1504.9%) < 0.01% $174,000 2022-05-13
Q4 2021 Added 4,892 +2,667 (119.9%) < 0.01% $16,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

13 managers reported VIRPAX PHARMACEUTICALS INC for Q1 2025.

Managers reporting VIRPAX PHARMACEUTICALS INC in Q1 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Tower Research Capital LLC TRC Reduced 0 -7,754 0 $0 5 qtrs
HRT FINANCIAL LP Reduced 0 -25,368 0 $0 2 qtrs
MORGAN STANLEY This report Reduced 0 -499 0 $0 5 qtrs
XTX Topco Ltd Reduced 0 -12,905 0 $0 2 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 0 -41,899 0 $0 3 qtrs
Vermillion Wealth Management Inc Reduced 0 -100 0 $0 2 qtrs
SBI Securities Co Ltd Reduced 0 -600 0 $0 2 qtrs
ADVISOR GROUP HOLDINGS INC Reduced 0 -240 0 $0 2 qtrs
Virtu Financial LLC Reduced 0 -23,657 0 $0 2 qtrs
UBS Group AG Reduced 0 -13,100 0 $0 4 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2025
Filed
May 15, 2025
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.